Publications

1. Dabigatran etexilate (Pradaxa) for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation

   For the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more risk ...

   Report | 06-06-2012

2. Assessment of the services provided by the Forensic Child Abuse Center

   The Forensic Medical Child Abuse Center asked CVZ to assess whether the various activities of the FPKM can be regarded as medical ...

   Report | 16-05-2012

3. Collagenase clostridium histolyticum (Xiapex) for the indication ‘treatment of Dupuytren's contracture

   On the basis of a comparison between collagenase studies and fasciectomy studies, no statement can be issued about the efficacy ...

   Report | 23-04-2012

4. Belimumab (Benlysta) for the indication ‘active, auto-antibodypositive systemic lupus erythematosus with a high degree of disease activity’

   The therapeutic value of adding belimumab to the standard treatment in the treatment of adult patients with active, ...

   Report | 23-04-2012

5. Assessment of the established medical science and practice of immunotherapy ch14.18 + GM-CSF + IL2 for highrisk neuroblastoma

   This leads to the outcome of assessment that immunotherapy ch14.18 + GM-CSF + IL2 in cases of high-risk neuroblastoma is still ...

   Report | 20-04-2012

6. Conditional reimbursement of health care

   Health care in the insured package must comply with the ‘established medical science and medical practice’ criterion. This ...

   Report | 06-04-2012

7. Rilpivirine-emtricitabine-tenofovir disoproxil (Eviplera) for the indication ‘infection with HIV-1’

   For the treatment of adult, therapy-naive patients infected with HIV-1 and with a virus concentration ≤ 100,000 copies/ml, the ...

   Report | 26-03-2012

8. Rilpivirine (Edurant) for the indication ‘infection with HIV-1’

   For the treatment of adult, therapy-naive patients infected with HIV-1 and with a virus concentration ≤ 100,000 copies/mL, the ...

   Report | 26-03-2012

9. rituximab (Mabthera) for the indication 'maintenance therapy for patients with follicular lymphoma

   For the maintenance treatment of follicular lymphoma patients who respond to first-line induction therapy, rituximab has an added ...

   Report | 27-02-2012

10. Ipilimumab (Yervoy) for ‘treatment of advanced (unresectable or metastatic) melanoma in adults

    In a single phase-3 study in patients with advanced (stage III or IV) melanoma who had been treated previously, and had a ...

    Report | 23-01-2012